MREO Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Mereo BioPharma Group plc Class Action

Core Viewpoint - A class action has been filed against Mereo BioPharma Group plc for allegedly misleading investors regarding the Phase 3 ORBIT and COSMIC studies for setrusumab, which did not meet their primary endpoints [2][3] Group 1: Allegations and Misleading Information - The complaint alleges that Mereo BioPharma provided investors with overly optimistic statements about the expected results of the Phase 3 ORBIT and COSMIC studies, claiming confidence in setrusumab's ability to reduce annualized fracture rates [2] - It is claimed that while making these positive statements, Mereo concealed material adverse facts about the true state of the Phase 3 studies, which ultimately did not achieve their primary endpoints [2] - The studies failed to show a reduction in annualized clinical fracture rates compared to placebo or bisphosphonate control groups, leading to artificially inflated prices for Mereo's American Depository Shares (ADS) [2] Group 2: Impact of the Announcement - On December 29, 2025, Mereo announced that neither the ORBIT nor the COSMIC studies met their primary endpoint, resulting in a significant decline in the price of Mereo's ADS from $2.31 to $0.29, a drop of over 87.7% [3] Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Mereo BioPharma, with a deadline to submit papers to serve as lead plaintiff by April 6, 2026 [4] - Shareholders do not need to participate in the case to be eligible for recovery and can remain absent class members if they choose [4]